INSM Latest Press Releases

-- November 4, 2026 --

Insmed to Present at November and December 2026 Investor Conferences PRNewswire 7:00 AM

-- October 29, 2026 --

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update PRNewswire 7:01 AM

-- October 20, 2026 --

Insmed Appoints Two New Directors to Its Board PRNewswire 7:00 AM

-- October 19, 2026 --

Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan PRNewswire 7:00 AM

-- October 15, 2026 --

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 PRNewswire 7:00 AM

-- October 14, 2026 --

Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 PRNewswire 7:01 AM

-- October 5, 2026 --

Insmed Announces CFO Transition PRNewswire 7:00 AM

-- September 21, 2026 --

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 PRNewswire 7:00 AM

-- September 16, 2026 --

Insmed Expands Community Impact During Fifth Annual Global Day of Good PRNewswire 7:00 AM

-- September 4, 2026 --

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PRNewswire 7:01 AM

-- September 3, 2026 --

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 PRNewswire 7:00 AM

-- August 26, 2026 --

Insmed to Present at September 2026 Investor Conferences PRNewswire 7:00 AM

-- August 24, 2026 --

BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease PRNewswire 7:00 AM

-- August 6, 2026 --

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update PRNewswire 7:01 AM

-- July 23, 2026 --

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 PRNewswire 7:39 AM

-- July 16, 2026 --

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension PRNewswire 7:00 AM

-- June 30, 2026 --

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors Globe Newswire 7:30 AM

-- June 23, 2026 --

Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory PRNewswire 7:01 AM

-- June 11, 2026 --

Nasdaq-100 Index June 2026 Quarterly Changes Globe Newswire 8:00 PM

Market Data Delayed 15 Minutes